Mano-Sousa Brayan Jonas, Ribeiro Lucas Antônio Lisboa, Alves Bruna Cristina, Gonçalves Ana Clara Anacleto, Silva Luiza Martins, Duarte-Almeida Joaquim Maurício
Campus Centro-Oeste, Universidade Federal de São João del-Rei, Divinópolis, Minas Gerais, Brazil.
Cannabis Cannabinoid Res. 2024 Feb;9(1):21-34. doi: 10.1089/can.2023.0200. Epub 2024 Jan 19.
The use of medical remains unregulated in several countries due to the scarcity of clinical studies with high scientific evidence that establish safety and efficacy of products. This study aimed to comprehensively analyze how knowledge has been created in this field, as well as perform a bibliographic mapping to identify knowledge gaps, and investigate key authors and journals that have significantly contributed to advancing our understanding of . The study protocol was registered in the International Prospective Register of Systematic Review (CRD42020223084). A systematic search was conducted in the Cochrane Central Register of Controlled Trials, Lilacs, Google Scholar, PubMed, SciELO, Scopus, and Web of Science databases. The bibliographic analysis and mapping were registered using the VOSviewer, Sci2tool, CiteSpace, and PoP software. The systematic search identified 27,597 records, with 17,020 duplicates, resulting in a total of 10,577 articles included. The authors who published the most were Marilyn Ann Huestis (=108) and Sagnik Bhattacharyya (=71), while Elisaldo A. Carlini and Raphael Mechoulam published 8 and 22 articles, respectively. The journals (=297), (=159) and (=150) were the ones that published the most on . The journals suggest that the articles are correlated with the adverse and toxicological effects of recreational use; however, most articles focus on medical . The peak of publications was in 2021 (=1,481). The countries that published the most were the United States (=9,735), while Brazil occupied the 11th position (=422). Most publications were carried out in "Pharmacology and Pharmacy" (11.31%), followed by "Psychiatry" (7.66%) and "Medicine" (5.80%). The areas of "Neurosciences" (1.59%), "Biochemistry," "Genetics," and "Molecular Biology" (0.79%) were little explored. This study captured the characteristics of publications about and clinical studies in the scientific literature, yielding >10,000 articles, representing a large literature review, to date. Therefore, the most productive countries included the United States, the United Kingdom, and Canada, while the most productive authors were Marilyn Ann Huestis and Sagnik Bhattacharyya, with a peak of publications in 2021. Finally, the most chosen journals were and .
由于缺乏能证实产品安全性和有效性的具有高度科学证据的临床研究，在几个国家，医用大麻的使用仍未得到规范。本研究旨在全面分析该领域知识是如何产生的，以及进行文献图谱绘制以识别知识空白，并调查对推动我们对医用大麻的理解有重大贡献的关键作者和期刊。该研究方案已在国际系统评价前瞻性注册库（CRD42020223084）中注册。我们在Cochrane对照试验中央注册库、Lilacs、谷歌学术、PubMed、SciELO、Scopus和科学引文索引数据库中进行了系统检索。使用VOSviewer、Sci2tool、CiteSpace和PoP软件进行文献分析和图谱绘制。系统检索共识别出27597条记录，其中17020条为重复记录，最终纳入10577篇文章。发表文章最多的作者是玛丽莲·安·休斯蒂斯（=108篇）和萨格尼克·巴塔查里亚（=71篇），而埃利萨尔多·A·卡里尼和拉斐尔·梅舒拉姆分别发表了8篇和22篇文章。发表文章最多的期刊是《[期刊名1]》（=297篇）、《[期刊名2]》（=159篇）和《[期刊名3]》（=150篇）。这些期刊表明文章与娱乐性大麻使用的不良和毒理学效应相关；然而，大多数文章关注医用大麻。发表量的峰值出现在2021年（=1481篇）。发表文章最多的国家是美国（=9735篇），而巴西位居第11位（=422篇）。大多数出版物发表在“药理学与药学”领域（11.31%），其次是“精神病学”领域（7.66%）和“医学”领域（5.80%）。“神经科学”（1.59%）、“生物化学”、“遗传学”和“分子生物学”（0.79%）领域的探索较少。本研究获取了科学文献中关于医用大麻及临床研究的出版物特征，产生了超过10000篇文章，是迄今为止一次大规模的文献综述。因此，产出最多的国家包括美国、英国和加拿大，产出最多的作者是玛丽莲·安·休斯蒂斯和萨格尼克·巴塔查里亚，发表量峰值出现在2021年。最后，最常被选用的期刊是《[期刊名1]》和《[期刊名2]》。
